Certara, a global biosimulation technology-enabled drug development and drug safety consulting company, is moving its corporate headquarters to a larger location in Princeton, N.J.
“Demand for our biosimulation solutions is increasing because it now is recognized by biopharmaceutical companies and regulatory agencies around the world as an integral part of the drug development process. Biosimulation can help to determine the appropriate dose for a drug entering clinical trials, identify possible drug-drug interactions, recommend the pediatric dose for a drug when there is only adult data available, and in some cases remove the need for conducting an additional clinical trial,” said Edmundo Muniz, M.D., Ph.D., Certara’s CEO.
“In addition, as the call for greater transparency in clinical studies grows louder and new regulations are introduced, biopharmaceutical companies are experiencing an increasing need for our Clinical Redaction Management Service, which removes private patient and company details from clinical trial information before it is published,” said Muniz.
Certara’s executive team will move into its new headquarters right away, where there is ample space for growth. In addition to increasing its executive team, Certara also plans to expand its business development, science, sales and marketing presence in Princeton. It also may add new members to its medical regulatory writing and consultancy teams.
This new location also includes a world-class education center in which Certara can conduct scientific and product training. Educating the life science industry on biosimulation, regulatory strategy and clinical trial data transparency and disclosure issues are core elements of the company’s mission.